91 related articles for article (PubMed ID: 19525194)
41. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
42. Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
Palayoor ST; Burgos MA; Shoaibi A; Tofilon PJ; Coleman CN
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4158-64. PubMed ID: 15217953
[TBL] [Abstract][Full Text] [Related]
43. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation.
Graff JR; Herman JG; Myöhänen S; Baylin SB; Vertino PM
J Biol Chem; 1997 Aug; 272(35):22322-9. PubMed ID: 9268383
[TBL] [Abstract][Full Text] [Related]
44. Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors.
Tirosh A; Mukherjee S; Lack J; Gara SK; Wang S; Quezado MM; Keutgen XM; Wu X; Cam M; Kumar S; Patel D; Nilubol N; Tyagi MV; Kebebew E
Cancer; 2019 Apr; 125(8):1247-1257. PubMed ID: 30620390
[TBL] [Abstract][Full Text] [Related]
45. [Ginsenoside 20(S)-Rg3 upregulates tumor suppressor VHL gene expression by suppressing DNMT3A-mediated promoter methylation in ovarian cancer cells].
Wang L; Han X; Zheng X; Zhou Y; Hou H; Chen W; Li X; Zhao L
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Jan; 41(1):100-106. PubMed ID: 33509760
[TBL] [Abstract][Full Text] [Related]
46. Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia.
Hatzimichael E; Benetatos L; Dasoula A; Dranitsaris G; Tsiara S; Georgiou I; Syrrou M; Stebbing J; Coley HM; Crook T; Bourantas KL
Leuk Res; 2009 Sep; 33(9):1272-5. PubMed ID: 19423161
[TBL] [Abstract][Full Text] [Related]
47. Loss of
Ford CA; Hurford IM; Fulbright LE; Curry JM; Peek CT; Spoonmore TJ; Cruz Victorio V; Johnson JR; Peck SH; Cassat JE
Front Cell Infect Microbiol; 2022; 12():985467. PubMed ID: 36204648
[TBL] [Abstract][Full Text] [Related]
48. Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications.
Hatzimichael E; Dasoula A; Kounnis V; Benetatos L; Lo Nigro C; Lattanzio L; Papoudou-Bai A; Dranitsaris G; Briasoulis E; Crook T
Leuk Lymphoma; 2012 Sep; 53(9):1709-13. PubMed ID: 22288719
[TBL] [Abstract][Full Text] [Related]
49. DNA methyltransferase 3A induces the occurrence of oral submucous fibrosis by promoting the methylation of the von Hippel-Lindau.
Kuang H; Yang L; Li Z; Wang J; Zheng K; Mei J; Sun H; Huang Y; Yang C; Luo W
Oral Dis; 2024 May; 30(4):2325-2336. PubMed ID: 37743610
[TBL] [Abstract][Full Text] [Related]
50. Interaction between the HIF-1α gene rs1957757 polymorphism and CpG island methylation in the promoter region is associated with the risk of anti-tuberculosis drug-induced liver injury in humans: A case-control study.
Chong Y; Zhu H; Ren Q; Ma X; Feng F
J Clin Pharm Ther; 2022 Jul; 47(7):948-955. PubMed ID: 35218216
[TBL] [Abstract][Full Text] [Related]
51. Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes.
Benetatos L; Dasoula A; Syed N; Hatzimichael E; Crook T; Bourantas KL
Leukemia; 2008 Jun; 22(6):1293-5. PubMed ID: 18094722
[No Abstract] [Full Text] [Related]
52. von Hippel-Lindau Protein Maintains Metabolic Balance to Regulate the Survival of Naive B Lymphocytes.
Xu S; Huo J; Huang Y; Aw M; Chen S; Mak S; Yip LY; Ho YS; Ng SW; Tan AH; Lee A; Ou X; Lam KP
iScience; 2019 Jul; 17():379-392. PubMed ID: 31351078
[TBL] [Abstract][Full Text] [Related]
53. Structural Basis for Modulation of Quality Control Fate in a Marginally Stable Protein.
Brock KP; Abraham AC; Amen T; Kaganovich D; England JL
Structure; 2015 Jul; 23(7):1169-78. PubMed ID: 26027734
[TBL] [Abstract][Full Text] [Related]
54. Suppressing APOE4-induced mortality and cellular damage by targeting VHL.
Jiang WI; Cao Y; Xue Y; Ji Y; Winer BY; Zhang M; Singhal NS; Pierce JT; Chen S; Ma DK
bioRxiv; 2024 May; ():. PubMed ID: 38464138
[TBL] [Abstract][Full Text] [Related]
55. Angiogenesis and multiple myeloma.
Giuliani N; Storti P; Bolzoni M; Palma BD; Bonomini S
Cancer Microenviron; 2011 Dec; 4(3):325-37. PubMed ID: 21735169
[TBL] [Abstract][Full Text] [Related]
56. [The bone turnover markers of myeloma bone disease].
Peng F; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):1030-3. PubMed ID: 25417887
[No Abstract] [Full Text] [Related]
57. Biochemical diagnosis of genetic disorders of the osseous skeleton.
Papatheofanis FJ
Med Hypotheses; 1988 Nov; 27(3):225-6. PubMed ID: 3211020
[TBL] [Abstract][Full Text] [Related]
58. A method and server for predicting damaging missense mutations.
Adzhubei IA; Schmidt S; Peshkin L; Ramensky VE; Gerasimova A; Bork P; Kondrashov AS; Sunyaev SR
Nat Methods; 2010 Apr; 7(4):248-9. PubMed ID: 20354512
[No Abstract] [Full Text] [Related]
59. Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Muylaert C; Van Hemelrijck LA; Maes A; De Veirman K; Menu E; Vanderkerken K; De Bruyne E
Front Oncol; 2022; 12():979569. PubMed ID: 36059621
[TBL] [Abstract][Full Text] [Related]
60. VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma.
Todorović L; Stanojević B
Biomol Biomed; 2023 Feb; 23(1):26-36. PubMed ID: 36036061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
